Clinical trial
Prospective, Multi-center, Randomized First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme eG (Electro Grafting) Based Biodegradable Polymer Sirolimus-eluting Stent and Resolute Integrity Zotarolimus-eluting Durable Polymer Stent in Patients With de Novo Coronary Artery Stenosis.
NCT02236975 is registered in ClinicalTrials.gov with Sino Medical Sciences Technology Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Multi-center, Randomized First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme eG (Electro Grafting) Based Biodegradable Polymer Sirolimus-eluting Stent and Resolute Integrity Zotarolimus-eluting Durable Polymer Stent in Patients With de Novo Coronary Artery Stenosis.
- Lead sponsor
- Sino Medical Sciences Technology Inc.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- April 30, 2015
- Completion date
- March 31, 2019
- Enrollment
- 168 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.